Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study

• Published in: Annals of surgical oncology 2011-10, Vol.18 (10), p.2997-3004
• Main Authors: Sun, Maxine, Abdollah, Firas, Budaüs, Lars, Liberman, Daniel, Tian, Zhe, Morgan, Monica, Johal, Rupinder, Schmitges, Jan, Shariat, Shahrokh F., Montorsi, Francesco, Greafen, Markus, Perrotte, Paul, Karakiewicz, Pierre I.
• Format: Article
• Language: English
• Subjects: Adult; Cohort Studies; Follow-Up Studies; Humans; Lymph Node Excision - utilization; Lymphatic Metastasis; Male; Medicine; Medicine & Public Health; Mortality - trends; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal - epidemiology; Neoplasms, Germ Cell and Embryonal - mortality; Neoplasms, Germ Cell and Embryonal - surgery; Oncology; Postoperative Complications; Prognosis; Retroperitoneal Space - surgery; SEER Program; Surgery; Surgical Oncology; Survival Rate; Testicular Neoplasms - epidemiology; Testicular Neoplasms - mortality; Testicular Neoplasms - surgery; United States - epidemiology; Urologic Oncology
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-011-1722-3

Background Retroperitoneal lymphadenectomy (RPLND), chemotherapy, and active surveillance represent treatment options for patients with nonseminomatous germ-cell tumors of the testis (NSGCTT). Our objective was to assess the utilization rate of RPLND in patients with NSGCTT. Methods Within the Surveillance, Epidemiology and End Results (SEER) cohort, 4,620 and 1,671 patients with stage I and II NSGCTT were diagnosed between the years 1988 and 2006. Univariable and multivariable logistic regression analyses were performed to test the predictors of RPLND use in respectively patients with stage I and II NSGCTT. Results The rate of RPLND according to stage I and II was 27 and 58%, respectively. In patients with stage I disease, the rate of RPLND decreased from 39% in 1988–1995 to 18% in 2004–2006 ( P